About Athersys
Athersys is a company based in United States founded in 1995. Athersys has raised $74.43 million across 16 funding rounds from investors including HHS, Invesco Mutual Fund and Helios. Athersys operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter United States
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website athersys.com
- Social LinkedIn X
- Legal Name Athersys, Inc.
- Annual Revenue$5.33 M (USD)-3.43as on Dec 31, 2022
- Net Profit-$72.53 M (USD)16.58as on Dec 31, 2022
- EBITDA-$75.59 M (USD)11.48as on Dec 31, 2022
- Total Equity Funding$74.43M (USD)
in 16 rounds
- Latest Funding Round$7.04M (USD), Post-IPO
Mar 2020
- InvestorsHHS
& 11 more
Funding Insights of Athersys
Athersys has successfully raised a total of $74.43M across 16 strategic funding rounds. The most recent funding activity was a Post-IPO round of $7.04 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $74.43M
- Total Rounds 16
- Last Round Post-IPO — $7.04M
- First Round $47.5M
(May 2000)
- Investors Count 12
Latest 10 of 16 funding rounds of Athersys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2020 | $7.04M | Post-IPO | – | – | |
| Nov 2019 | $100M | Post-IPO | – | – | |
| Aug 2017 | $83,408 | Grant | – | – | |
| Sep 2016 | $944,055 | Grant | – | – | |
| Jul 2015 | $212,796 | Grant | – | – | |
| Nov 2013 | $20M | Post-IPO | – | – | – |
| Aug 2013 | $1.76M | Grant | – | – | |
| Mar 2012 | $9M | Post-IPO | – | – | – |
| Sep 2010 | $99,302 | Grant | – | – | |
| Aug 2010 | $99,302 | Grant | – | – |
12 investors in total: 12 institutional.
Investors in Athersys
Athersys has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Invesco Mutual Fund and Helios.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Greenleaf Capital Partners is engaged in investment and business consulting. | 2012 | greenleafcp.com | Creve Coeur, United States | |
Government-backed investments are directed toward healthcare, fintech, and various sectors. | – | edbi.com | Singapore, Singapore | |
- | – | roxburycap.com | - | |
Investment bank | – | aspirecapital.in | Kolkata, India | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
- | – | vanwagoner.com | - | |
- | – | cogenebiotech.com | - | |
- | – | curranpartners.com | - | |
Diversified trading firm providing liquidity and technology solutions in finance. | 1992 | drw.com | Chicago, United States | |
Fund based investment management firm and fund of funds focused on multiple sectors | 1935 | invescomutualfund.com | Mumbai, India |
Investor details for Athersys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Athersys
6 people are tracked at Athersys (3 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Robert Mays | EVP & Head, Regenerative Medicine & Neuroscience Programs | Leadership |
David Russ | Vice President Supply Chain, Finance And Administration At Athersys | Leadership |
Brooke Dapolito, MBA | Director, Regulatory Project Management | Leadership |
Jack L Wyszomierski | Director | Board & advisors |
Ismail Kola | Chairman | Board & advisors |
Joe Nolan | Director | Board & advisors |
Complete people profiles for Athersys
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Athersys
Athersys is a publicly listed company on the OTC with ticker symbol ATHXQ in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Aug 2022
- Listed onNASDAQ: ATHX
- Listed entityAthersys, Inc.
- Exchange sectorHealth technology
- ISINUS04744L2051
- Share price$0.00 (-90% on the day) · 2026-10-06
- Market capitalisation$61.72
- Volume (last session)634
Financials of Athersys
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | $5.3M | -$72.5M | -$75.6M |
| 2021 | $5.5M | -$87.0M | -$85.4M |
| 2020 | $1.4M | -$78.8M | -$77.4M |
Detailed financial statements for Athersys
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Athersys
4 dated milestones of Athersys across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Athersys is founded.
- Funding First funding round of $47.5M.
- Funding Latest funding round, Post-IPO, of $7.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Athersys
Athersys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| unither.com | 1998 | Silver Spring, United States | – | 1,168 | Treatments for chronic and life-threatening diseases are developed and commercialized. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| eisai.com | 1941 | Tokyo, Japan | – | 10,419 | Drugs for oncology and neurological disorders are developed by Eisai. |
Detailed competitors of Athersys
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Athersys
The website of Athersys (athersys.com) receives about 1.7K visits a month and ranks #8,716,189 among all websites worldwide, #7,465 in Biotechnology and Pharmaceuticals.
- Monthly visits1.7K
▼ 10.6% vs previous month
- Global rank#8,716,189
among all websites
- Category rank#7,465
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.6
- Average visit15 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with Athersys. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cescatherapeutics.com | 100% | – | – | View details | |
| archtherapeutics.com | 97% | 1.7K | #7,558,673 | View details | |
| actiniumpharma.com | 96% | 6.2K | #3,668,195 | View details | |
| ocutx.com | 94% | 12.7K | #1,928,176 | View details | |
emcell.com | emcell.com | 71% | – | #8,070,062 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Athersys
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Athersys
Complete news archive for Athersys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Athersys
10 companies that operate in the same segment as Athersys (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Athersys
Athersys was founded in 1995 and raised its 1st funding round 5 years after it was founded.
Athersys is headquartered in United States.
Athersys is a funded company, having raised a total of $74.43M across 16 funding rounds to date. The company's 1st funding round was a Grant of $99.3K, raised on May 2000.
Annual revenue of Athersys is $5.33M as on Dec 31, 2022.
Athersys engaged in the discovery and development of therapeutic product candidates to treat different cardiovascular, neurological, inflammatory diseases. Its product portfolio includes MultiStem, a stem cell product, which is being developed as a treatment for multiple disease indications such as Ischemic stroke, Acute myocardial infarction, Inflammatory bowel disease. In addition, the Company is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, and narcolepsy or other forms of excessive daytime sleepiness.
Athersys's top competitors include Merck, Roivant Sciences and AbbVie.
Yes, Athersys is publicly traded on OTC under the ticker symbol ATHXQ.
Athersys has 12 investors. Key investors include HHS, Invesco Mutual Fund, Helios, Aspire Capital, and Greenleaf Capital Partners.